Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

On Thursday, Ionis Pharmaceuticals Inc (IONS) stock saw a decline, ending the day at $38.49 which represents a decrease of $-0.67 or -1.71% from the prior close of $39.16. The stock opened at $39.07 ...

While success is far from guaranteed in bio-land, with this week’s raising, Percheron has the horsepower to have a decent ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its price target reduced by equities researchers at Guggenheim from $70.00 to $65.00 in a report released on Wednesday, Benzinga reports.

Handelsbanken Fonder AB increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 26.8% in the third quarter, according to its most recent disclosure with the SEC.

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that the FDA has granted a Fast Track designation to its investigational RNA ...

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility. Investments in a currency other than sterling are exposed to currency exchange ...